Glioblastoma is an aggressive, often recalcitrant disease. In the majority of cases, prognosis is dismal and current therapies only moderately prolong survival. Immunotherapy is increasingly being recognized as an effective treatment modality. CD70 is a transmembrane protein that shows restricted expression in tissue but has been described in various malignancies. Therapeutic targeting of CD70 has demonstrated antitumor efficacy and is in clinical trials. Here, we sought to characterize CD70 expression in a large cohort of gliomas (n ¼ 205) using tissue microarrays. We identified a subset of tumors (n ¼ 18, 8.8% of high-grade gliomas) exhibiting moderateto-strong immunoreactivity that enriched for the IDH-wild-type glioblastoma variants gliosarcoma (n ¼ 10) and the newly described epithelioid glioblastoma (n ¼ 4). CD70 expression was associated with prolonged survival in gliosarcoma. Analysis of TCGA datasets showed significantly increased CD70 expression in mesenchymal tumors and prolonged survival in recurrent non-G-CIMP highexpressing tumors. In CD70þ gliomas, there was a significant increase in CD68/CD163/HLA-DRþ tumor-associated macrophages, but not CD27þ TIL. These results confirm prior in vitro studies and demonstrate expression in a clinical cohort. The absence of CD70 expression in the post-treatment setting may portend more clinically aggressive disease in gliosarcoma. However, larger-scale studies will be needed to characterize and validate this relationship.
INTRODUCTION
Novel immunologic approaches have led to significant breakthroughs in cancer therapy in recent years. Notable examples include the cytotoxic T-lymphocyte antigen 4 (CTLA-4) check point inhibitor ipilimumab in unresectable/ metastatic melanoma (1), the PD-1 (CD279) inhibitors nivolumab and pembrolizumab in advanced non-small cell lung cancer (NSCLC) and melanoma (2, 3) , and chimeric antigen receptor (CAR)-modified T cells targeting CD19 in hematologic malignancies (4, 5) . Immunotherapeutic targets under investigation for diffuse gliomas include the mutant epidermal growth factor receptor variant III (EGFRvIII) (6) , K27 demethylase in H3.3K27 mutant tumors (7), the R132H mutation in IDH (8) , and the PD-1/PD-L1 axis [see (9) for review]. Therapies targeting the co-stimulatory network (eg PD-1/PD-L1, CTLA-4/B7-1) are increasingly being used for the treatment of solid tumors.
CD70 is a type II transmembrane protein and member of the tumor necrosis factor (TNF) family (10, 11) . Also known as CD27 ligand (or CD27L), CD70 interacts with its receptor CD27 (constitutively expressed on CD4þ and CD8þ T cells) to regulate cytotoxic T-cell activation, cell proliferation, and survival (12) . Expression is normally restricted to activated immune cells and thymic stromal cells (13) ; however, aberrant expression has been reported in several malignancies, including renal cell carcinoma (14) , leukemia/lymphoma (15) , NSCLC (16) , thymic carcinoma (17) , osteosarcoma (18) , and melanoma (19) . Clinical trials evaluating CD70 as a therapeutic target include the use of antibody-drug conjugates (Clinicaltrials.gov identifier: NCT02216890, NCT01015911), enhanced antibody-dependent cellular cytotoxicity with an anti-CD70 monoclonal antibody (NCT01813539, NCT02759250), and CAR-T cell therapy (NCT02830724).
Expression of CD70 has been demonstrated in glioma cells at both the mRNA and protein level (20, 21) . CD70 expression in glioma cells has also been shown to be radioinducible as a p53-independent response (21) . While reports of CD70 protein expression in tissue are limited, immunoreactivity has been shown in anaplastic astrocytoma and glioblastoma (21) .
An in-depth evaluation and illustration of CD70 expression in a large patient cohort, however, has yet to be reported. Here, we characterize a subset of high-grade gliomas that show strong cell surface expression of CD70, and we describe its association with clinical, histologic, and immunophenotypic features. Given the often marked infiltration of tumorassociated macrophages (TAM) in high-grade gliomas and their association with tumor progression and prognosis (22) , we also evaluated the immune microenvironment using markers of macrophage lineage (CD68/CD163/HLA-DR), as well as CD27 expression in T-cells. Lastly, to support our findings, we also surveyed The Cancer Genome Atlas (TCGA) glioma datasets to correlate CD70 mRNA expression levels with overall survival and gene expression-based subtypes. These findings provide evidence from a clinical cohort for the potential therapeutic targeting of CD70 in a subset of high-grade gliomas.
MATERIALS AND METHODS

Case Selection and Tumor Classification
Archival tissues were procured from the National Institutes of Health/National Cancer Institute (NIH/NCI) in Bethesda, Maryland (2000 Maryland ( -2016 . All patients were deceased at the time of evaluation and were exempt from Institutional Review Board review. At the time of the original diagnosis, cases were classified according to the 2007 WHO Classification of Central Nervous System Tumors (23). Using an integrated diagnostic approach that incorporates histology, immunohistochemistry, and molecular data (where available), cases were re-reviewed and assigned to the newest diagnostic categories outlined in the 2016 WHO classification system (24) (see below for interpretation of immunohistochemistry). Fluorescence in situ hybridization (FISH) for 1p/19q codeletion was retrospectively included as part of the original case work-up in our lab.
The IDH-wildtype variants gliosarcoma and epithelioid glioblastoma (E-GBM) were diagnosed based on previously reported histologic features . Briefly, cases of gliosarcoma contained a biphasic population of neoplastic cells consisting of a malignant glial component (GFAPþ) and a sarcomatous component composed of overtly neoplastic cells enmeshed in a dense pericellular reticulin meshwork; these 2 areas were often, but not always, regionally distinct. E-GBM contained a monotonous population of round, occasionally discohesive cells with eosinophilic cytoplasm, eccentric nuclei, and prominent nucleoli. No eosinophilic granular bodies or Rosenthal fibers were noted. Focally, areas of spindled cells were occasionally present in an otherwise predominant population of epithelioid cells.
Tissue Microarrays (TMA)
Hematoxylin and eosin (H&E) sections from formalinfixed paraffin-embedded (FFPE) tissue blocks were evaluated for adequate tumor content. Due to the marked morphologic, immunophenotypic, and molecular heterogeneity in diffuse gliomas, 4-mm tissue cores were used for construction. Tissue cores were extracted from donor paraffin blocks and manually aligned in a melted paraffin bath using a pre-defined grid. Each block contained 28 cores and a 2-mm control tissue marker (liver, kidney, or lymph node) that also served as a spatial reference. H&E-stained sections were then reviewed to confirm representative tumor sampling and accurate core placement.
Immunohistochemistry and Staining Evaluation
Immunohistochemical staining was performed on 4-mmthick tissue sections with a Ventana BenchMark Ultra (IDH1  R132H, ATRX, p53, H3K27M, EGFR, INI1, GFAP, CD68,  CD163 , HLA-DR, Ki-67; Ventana Medical Systems, Tucson, AZ), Ventana XT (CD27), or Leica Bond (CD70; Leica Microsystems, Bannockburn, IL) automated immunostainer using manufacturer recommended antigen retrieval. Antibody names, clones, dilutions, source, and expected cellular localization are listed in Table 1 . For CD70 staining, a range of dilutions (1:500-1:2000) was tested, with a final dilution of 1:500 used for evaluation. Cases were deemed as having true expression when they exhibited crisp membranous staining or unequivocal strong cytoplasmic staining in tumor cells that was stronger than adjacent non-neoplastic tissue (neuropil, RBCs, vessel media, and adventitia). While a subset of activated lymphocytes express CD70 under normal conditions, absence of staining in adjacent immune cells provided an internal control.
Immunoreactivity for CD70 was assessed using both quantitative and semi-quantitative methods. For semiquantitative analysis, expression in tumor cells was scored as follows: 0 (negative); 1 (<5% of tumor cells); 2 (5-50% of tumor cells); or 3 (>50% of tumor cells). The cut-off used here (5%) is based on the commonly reported staining threshold used for PD-L1 expression, another co-stimulatory molecule (28) . Tumor cells showing weak granular cytoplasmic staining (and a corresponding absence of moderate or strong membranous staining) in any number of tumor cells were given a score of 1. Quantitative methodology is described below. Full tissue sections from positive TMA cases (n ¼ 18) were subsequently stained with anti-CD70 to assess the distribution and heterogeneity of staining. Evaluation of morphologic and immunohistochemical features allowed separation of expression on tumor cells rather than macrophages/microglia to interrogate the association of CD70-positivity and TAM.
IDH mutation status was determined primarily by immunohistochemistry. For designation as IDH-wild-type, a cutoff of 10% was used, where the probability of a variant IDH1 or IDH2 mutation was calculated using a predictive model for IDH mutations in grade II-IV astrocytomas and oligodendrogliomas (29) . Cases not meeting the 10% cutoff were designated as not otherwise specified. All gliosarcoma and epithelioid glioblastoma cases were designated as wildtype for IDH; these histologic variants did not show reactivity with anti-IDH R132H. All other surrogate markers were interpreted based on their reported sensitivity and specificity (see Ref. [30] for review). For p53, staining was scored as positive (predictive of p53 mutation) when !10% of tumor cells demonstrated moderate or strong nuclear immunoreactivity (31) . EGFR was scored as positive when tumor cells showed moderate to strong (2-3þ) membranous staining; EGFR immunohistochemistry was mainly used in the context of negative staining (i.e. EGFR amplification is virtually never seen with negative EGFR immunohistochemistry, and has a reported negative predictive value of 0.99-1) (32).
Digital Imaging and Automated Analysis
TMA slides and select case slides from the original paraffin blocks were digitally scanned and converted to whole slide images using the Aperio XT system (Leica Biosystems, Buffalo Grove, IL) at 40Â magnification and viewed with Aperio Imagescope software (version 11.2). Tumor areas on TMAs and fresh-cut full sections were digitally annotated with regions of interest for analysis. Staining was quantified using the positive pixel count v9 (ppc; CD70, CD27, and CD163) and nuclear v9 (p53) algorithms and reported as the percentage of positive staining of the tumor area analyzed (irrespective of cellular localization for ppc). Bright-field images were extracted from Imagescope and captured using the Nuance multispectral imaging system (PerkinElmer, Waltham, MA).
BRAF V600E
BRAF V600E testing was performed on FFPE sections of E-GBM cases. DNA was extracted from paraffinembedded tissue sections using the Qiagen QIAamp DNA FFPE Tissue Kit. The DNA was diluted to an appropriate concentration and subjected to droplet digital PCR for detection of BRAF V600E (c.1799C > A), using a Bio-Rad QX200 Droplet Digital PCR System. In brief, following droplet generation in the QX200 droplet generator, PCR was performed in a 96 well microtiter plate with a single primer set encompassing position c.1799 of the BRAF gene, and amplification products were detected with two allele specific competitive probes, one to wild-type sequence c.1799T (labeled with HEX) and a second to the mutant sequence c.1799A (labeled with FAM) which results in the BRAF p. V600E mutation. Individual droplets were analyzed in the QX200 droplet reader using a 2-color fluorescence detection system and quantitation of the mutant allele fraction was performed with QuantaSoft software. All positive and negative control reactions were adequate. The BRAF V600E (c.1799T > A) ddPCR mutation assay as implemented and validated in our laboratory has a lower limit of detection of 0.1% mutant allele fraction.
TCGA Datasets
Expression levels and clinical data from TCGA (http:// cancergenome.nih.gov) and Vital (33) cohort datasets were obtained through the GlioVis data portal for visualization and analysis of brain tumor expression datasets (http://gliovis.bio info.cnio.es, accessed May 29, 2017) (34) . Using RNAseq and the Affymetrix U133A Array (HG-U133A) data, CD70 mRNA expression levels were acquired from 447 TCGA GBM samples and correlated with overall survival (Affymetrix) and gene expression-based subtype (ie neural, proneural, mesenchymal, and classical) (RNAseq). For generation of survival curves in the recurrent, non-G-CIMP dataset, the median mRNA cutoff (5.32285) was used for defining high and low expression of CD70. Mutation frequency from the TCGA was obtained from cBioPortal (http://www.cbioportal.org, accessed May 29, 2017) (35, 36) .
Statistical Analysis
Differences among groups were determined using a Kruskal-Wallis test. Individual 2-group tests were performed using a Wilcoxon rank sum test. In the cases in which several 2-group comparisons were made after using a Kruskal-Wallis test to overall the overall difference among groups, the Hochberg method was used to adjust the p values for multiple comparisons (37) . All p values are 2-tailed. Survival analysis was performed using the Kaplan-Meier estimation and log-rank test. For TMA data, survival was calculated (in months) from the date of tumor detection by imaging (overall survival) and the time (months) from the last date of radiotherapy (post-radiation survival) until the date of death. No censored events were included in the TMA analyses; this limited bias is being reported but is not expected to materially impact the interpretation of the findings due to the relatively short survival of patients with glioblastoma following treatment. Analysis of tissue microarray and TCGA data was performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC) and illustrated in Microsoft Excel. A p value <0.05 was considered statistically significant.
RESULTS
Clinicopathologic Features
A total of 214 patients, including 12 paired patient samples (primary and recurrent tissue from the same patient), were included in the initial study cohort. Of these, 9 cases (7 diffuse midline gliomas and 2 IDH-wild-type glioblastomas)
showed diminished immunoreactivity with a number of the antibodies tested. In our experience, staining for ATRX (HPA001906) routinely shows decreased immunoreactivity in the presence of tissue artifacts (e.g. prolonged fixation). As a consequence, cases showing loss of normal internal positive control (vessel endothelial cells, non-neoplastic cells such as neurons and glia, etc.) with anti-ATRX were excluded from further analysis. A total of 205 tumor tissues were suitable for evaluation. Patient demographics and clinical characteristics are outlined in Table 2 . Classification of tumors according to the 2016 WHO Classification of Central Nervous System Tumors are shown in Table 3 . The majority of cases (90.1%) were assigned to the following 2016 WHO diagnostic categories: anaplastic astrocytoma, IDH mutant (n ¼ 23); glioblastoma, IDH mutant (n ¼ 15); glioblastoma, IDH-wild-type (n ¼ 96); glioblastoma, not otherwise specified (n ¼ 29); diffuse midline glioma, H3 K27M mutant (n ¼ 16). A subset of evaluable diffuse midline gliomas were negative for H3K27M by immunohistochemistry (n ¼ 5).
A spectrum of staining for CD70 was observed, ranging from focal, weak and cytoplasmic to strong and diffuse cell surface (membranous) expression. Eighteen cases (8.8% of high-grade gliomas) exhibited moderate-to-strong staining (present in >5% of tumor cells and scored as 2 or 3). As a group, these high-expressing cases showed similar histologic and clinical features (see below) and were grouped together for subsequent analysis and illustration. Forty-eight cases (23.4% of all tumors) showed rare weak positive or diffuse Table 4 for complete tumor immunophenotypes).
CD70 Is Expressed in the IDH-Wild-type Variants Gliosarcoma and Epithelioid Glioblastoma
A predominant histologic pattern emerged in cases with moderate-to-strong expression, characterized by either focal or diffuse epithelioid cellular morphology (n ¼ 4/4 E-GBM tested; Fig. 1 ) or sarcomatous transformation (n ¼ 10/16 gliosarcomas tested; Fig. 2 ). E-GBM is a newly described, but rare, variant of IDH-wildtype glioblastoma with distinct morphologic and molecular features. In our cohort, 4 tumors met histologic criteria for this designation, as it has been recently defined (24) (Fig. 1A-C) ; BRAF V600E mutation was negative in 3 of these cases. The single case that was V600E positive showed a strong cytoplasmic pattern of staining with focal membranous immunoreactivity, compared to the crisp and diffuse membranous staining observed in the remaining three V600E negative E-GBM cases. Staining for cytokeratins (CAM5.2) was focally present in a majority of CD70-positive tumors, both in gliosarcoma (n ¼ 5) and E-GBM (n ¼ 3) (Fig. 1E) . By comparison, only 1 out of 4 CD70-negative gliosarcomas showed immunoreactivity with CAM5.2. Expression of CD70 in gliosarcoma was often restricted to reticulin-rich, GFAP-poor areas (Fig.  2D, I ). In our study, all but one gliosarcoma were secondary (ie prior diagnosis of high-grade glioma with subsequent radiation; n ¼ 10/14 with available history). A case of primary gliosarcoma (i.e. arising de novo with no history of high-grade glioma and radiation prior to gliosarcoma diagnosis) was included and showed rare staining for CD70 in <5% of tumor cells. No radiation-induced gliosarcomas (i.e. arising post-radiation without a history of high-grade glioma) were evaluated in this study. No tumors, including those containing an epithelioid morphology, showed evidence of SMARCB1 (hSNF5/INI1) gene alterations (i.e. INI1 expression retained on immunohistochemistry) (Fig. 1F) . CD70 expression in an anaplastic oligodendroglioma (IDH-mutant and 1p/19q co-deleted) and a diffuse midline glioma, H3 K27M-mutant tumor was also identified (Fig. 3G-J) . Representative images of CD70-negative cases are shown in Supplementary Data Figure S1 . Quantitative analysis of all tumoral areas; this included both sarcomatous and gliomatous components in gliosarcoma cases. This may artificially reduce the ppc since CD70 staining was frequently restricted to sarcomatous areas in gliosarcoma.
Abbreviations: GS, gliosarcoma; E-GBM, epithelioid glioblastoma; DMGH3M, diffuse midline glioma H3 K27M mutant; AOIDHM, anaplastic oligodendroglioma, IDH mutant and 1p19q co-deleted.
n/a, not applicable; np, not performed.
Analysis of CD70 expression across the groups using the 2016 WHO classification showed disproportionate, but non-significant, expression in IDH-wild-type glioblastoma (p ¼ 0.11) (Fig. 4A) . Stratification by IDH-wild-type variants showed a significantly higher percentage of CD70 expression in gliosarcoma and E-GBM compared to IDH-wild-type glioblastomas with classic histologic features, as well as to the remaining diagnostic entities (p < 0.05; Fig. 4B ). In a separate dataset (Vital cohort), mRNA expression was shown to be higher in gliosarcoma (n ¼ 2) compared to glioblastoma samples (n ¼ 26) (Fig. 4C) . Additionally, data from the TCGA datasets showed CD70 mRNA expression to be significantly higher in mesenchymal tumors compared to neural, proneural, and classical gene expression-based subtypes (based on subtype signatures by Verhaak et al. (38) ) (p < 0.001; Fig. 4D) . A significant correlation between CD70 mRNA and protein expression has previously been described (21) .
Expression of CD70 Is Associated With Prior Radiotherapy and Improved Survival in Secondary Gliosarcoma
Of the samples that were obtained after radiation treatment and with available history (n ¼ 14), all but 1 case demonstrated moderate-to-strong CD70 expression (Table 5) . Survival analysis showed significantly prolonged post-radiation survival in cases of gliosarcoma with moderate-to-high (2-3) expression of CD70 compared to CD70 low or negative (0-1) gliosarcoma (p < 0.05; Fig. 5A ). Overall survival in gliosarcomas based on CD70 expression showed a trend towards increased survival in CD70-positive tumors (groups 2-3 vs groups 0-1, p ¼ 0.062; Fig. 5B ). The remaining comparisons showed no significant differences in post-radiation or overall survival. Comparison of paired primary and recurrent tumor samples included CD70-positive (n ¼ 3) and CD70-negative (n ¼ 9) post-radiation samples. In these groups, all treatment naïve tumors (primary diagnosis, n ¼ 12) were negative or showed rare weak cytoplasmic CD70 staining. Hence, 3 paired cases showed newonset moderate-to-strong expression of CD70 at recurrence after radiotherapy. The time from the last dose of radiation to CD70 staining at recurrence ranged from 6 to 58 months; this was similar to cases without post-radiation CD70 expression (4-50 months). Similar to our findings, analysis of TCGA data showed shorter overall survival in recurrent non-G-CIMP tumors with low CD70 mRNA expression (n ¼ 6, median 17.3) compared to high CD70 mRNA expression (n ¼ 6, median 51.05) (p < 0.01; Fig. 5C ).
CD1631 Tumor-Associated Macrophages Are Significantly Increased in HGG With Moderateto-Strong Expression of CD70 Without an Accompanying Increase in CD271 TIL
Expression in all tumors with moderate-to-strong CD70 expression was coupled with a significant increase in CD163þ TAM (p < 0.05; Fig. 6 ). Staining for CD68 and HLA-DR showed a similar distribution of expression to CD163 (Supplementary Data Fig. S2 ). Additional comparisons of TAM, including CD70þ/À gliosarcomas, were not significant. There was no significant increase in CD27þ TIL in all group comparisons.
DISCUSSION
Despite therapeutic progress in neuro-oncology, a diagnosis of glioblastoma continues to portend a poor prognosis with a 5-year overall survival recently reported at 5.5% (39) . As mentioned previously, the two major classes of immunotherapy, checkpoint inhibitors and adoptive cell therapy, have demonstrated success in treating clinically advanced cancers. Accordingly, immune checkpoint blockade using anti-CTLA4 (tremelimumab, ipilimumab), anti-PD-L1 (durvalumab), and anti-PD1 (nivolumab) therapies are currently being evaluated in clinical trials for glioblastoma (NCT02794883, NCT02311920). Expression of CD70 in glioma cells, and its subsequent interaction with CD27 on B and T cells, has been shown to have immunosuppressive functions on the tumor microenvironment via T-cell apoptosis (21, 40) . Anti-tumor efficacy has been demonstrated with targeted therapies against CD70-expressing tumors . Here, we show that CD70 may be a viable therapeutic target in a subset of gliomas as it is predominantly expressed in the IDH-wild-type glioblastoma variants gliosarcoma and epithelioid glioblastoma. Consistent with in vitro studies, we found that moderate-to-strong expression was largely observed in tumors with prior radiation. In secondary gliosarcomas, we show an association of CD70 expression with improved prognosis following radiation. Expression of CD70 in high-grade gliomas was also accompanied by a significant increase in tumor-associated macrophages.
The CD27-CD70 co-stimulatory axis is highly regulated and serves to stimulate effector and memory T-cells, as well as promote immune cell survival through prevention of apoptosis (44, 45) . Expression of CD70 is normally restricted to activated T and B cells, thymic epithelial cells, and dendritic cells in the intestinal mucosa (46) . CD70 expression has been demonstrated in 5 of 12 glioblastomas and 3 of 4 anaplastic astrocytomas (21) . Reports of CD70 expression in gliomas have shown expression to be preferentially localized within cell processes and in a "stippled" pattern within the cell soma (20) ; this latter finding is consistent with our own observations with CD70 immunohistochemistry in patient tissue.
Expression of CD70 is inducible by radiation exposure in glioma cells and is thought to alter antitumor responses through proapoptotic effects (21, 47) . This mechanism of immune evasion by gliomas was confirmed in a separate study showing attenuation of T-cell death following addition of an anti-CD70 antibody (40) . While an association with prior radiation is suggested by our findings in vivo, this may reflect the post-therapeutic nature of cases seen at our institution. It should be noted, however, that 97% (35/36) of treatment-naïve (prior to radiation) high-grade gliomas in our study were negative or only weakly positive for CD70. Furthermore, matched patient tumor samples in our cohort showed expression of CD70 in recurrent post-radiation samples in 3 of 12 cases. Taken together, this suggests that radiation-induced expression of CD70 in high-grade gliomas is more likely to occur in a subset of tumors with specific histopathologic features. Additionally, when accompanied by a sarcomatous phenotype (ie gliosarcoma) at recurrence, moderate-to-strong CD70 expression may signal a better clinical outcome. This will need to be confirmed within a larger cohort of matched pre-and postradiotherapy samples.
Aberrant expression of CD70 in tumors may be mediated by tumor-specific mechanisms. A recent study identified recurrent mutations, chromosomal deletions, and promoter methylation of the CD70 gene (TNFSF7) as a mechanism of oncogenesis in diffuse large B-cell lymphoma (DLBCL) (48) . Promoter methylation has also been implicated in breast cancer progression through silencing of the CD70 gene (49) . Additionally, drug-induced overexpression of CD70 has been shown in T-cells through TNFSF7 promoter demethylation (50) . Alterations in pVHL, the protein product of the VHL gene, through mutations, epigenetic changes, and hypoxia inducible factor (HIF) deregulation, led to overexpression of CD70 in clear cell RCC (51) . To ascertain whether genomic alterations in CD70 occur in high-grade gliomas, we surveyed TCGA datasets (http://www.cbioportal.org) (35, 36) . Alterations in CD70 were an infrequent event in high-grade gliomas (0.4%), suggesting other mechanisms for its expression at the protein level. Interaction with the microenvironment, evidenced by the marked increase in macrophages observed in our cohort, suggests possible immune-mediated expression, or may represent a therapy-related response by the tumor cells.
Macrophages and microglia are the predominant immune cell population in gliomas, comprising an estimated 30%-50% of the tumor mass (52, 53) . Macrophages are known to promote infiltration and tumor growth through the secretion of cytokines and chemokines such as metalloproteases (MT1-MMP) and colony stimulating factors (see (54) for review). Tumor growth is further potentiated with polarization of activated macrophages to the M2 phenotype. Glioma-associated macrophages generally do not express costimulatory molecules (CD70, CD80, and CD86), but express major histocompatibility complex II that is required for T-cell priming in the host anti-tumor response (55) . Using markers commonly employed as M2 surrogates, we showed a significant increase in CD163/CD68/HLA-DRþ TAM associated with CD70 expression by tumor cells. The absence of increased CD27þ T-cells in our tumors is consistent with the normal downregulation and shedding of CD27 following interaction with CD70 (56) . This interaction also leads to Tcell apoptosis, a mechanism exploited by glioma tumor cells in immune evasion (40) . The increased TAM observed here Survival (months) from the last date of radiation (rx) to death. F, frontal; T, temporal, P, parietal; BS, brainstem; PO, parieto-occipital; TP, temporoparietal; GB, glioblastoma; DIPG, diffuse intrinsic pontine glioma; AO, anaplastic oligodendroglioma; GS, gliosarcoma; E-GBM, epithelioid glioblastoma; DMGH3M, diffuse midline glioma, H3 K27M mutant; ST, subtotal resection; GTR, gross total resection; P, partial resection; GW, Gliadel (carmustine) wafer; GFN, gefitinib; TMZ, temozolomide; ENZ, enzastaurin; LAP, lapatinib; CAR, carmustine; THAL, thalidomide; BVZ, bevacizumab; CRB, carboplatin; VAN, vandetanib; IND, indoximod; DAB, dabrafenib; GK, gamma knife radiation; EBR, external brain radiation.
FIGURE 5. Kaplan-Meier estimation of survival probability. Gliosarcomas showing moderate-to-strong expression of CD70 (>5% of tumor cells) showed an association with prolonged post-radiation survival compared to gliosarcomas with negative or weak expression, as measured from the last date radiation to death (p < 0.05) (A). Comparison of overall survival in the same groups showed a trend towards significance (p ¼ 0.062) (B). Survival estimation generated from TCGA data in non-G-CIMP tumors showed significantly shorter overall survival in recurrent tumors with low CD70 mRNA expression compared to tumors with high expression (p < 0.01) (C).
may reflect the overall increase in macrophages seen with escalating grade in diffuse gliomas (57, 58) . However, after adjusting for treatment status and grade, we found CD163þ TAM in CD70-expressing high-grade gliomas was significantly greater when compared to CD70-negative tumors. This suggests a possible functional association between TAM and CD70-expressing glioma cells.
Given the relative low frequency of CD70 expression in diffuse gliomas overall, its role as a diagnostic and/or prognostic marker is unclear. Using a 10% threshold of tumor cells with moderate-to-strong staining (a referenced cut-off used in hormone receptor-positive breast cancer), an association with shorter survival and "resistant" disease was noted in CD70þ ovarian carcinomas (59) . Shorter overall survival has been reported in DLBCL (both germinal center and activated B-cell like profiles) with high CD70 mRNA expression and in DLBCL (activated B-cell like) with promototer hypomethylation of the CD70 gene (48) . In clear cell renal cell carcinoma, shorter survival was seen in tumors with high CD70 expression when associated with increased CD27þ TILs (51) . Conversely, no association with CD70 expression and overall survival was seen in head and neck squamous cell carcinoma (60) . The association of CD70 expression with survival in post-radiation gliosarcomas raises interesting biologic and therapeutic possibilities. Initial in vitro studies demonstrated CD70-mediated immune cell apoptosis as a mechanism of immune escape in gliomas (21) . Subsequent work, however, showed immune stimulatory effects in vivo, and concluded that CD70 expression alone is not sufficient to generate an anti-tumor response (47) . Interestingly, a soluble form of CD70 (sCD70) was shown to stimulate a CD8þ T-cell-dependent anti-glioma response in a syngeneic mouse model (61) . Taken together, induction of tumor cell killing through targeted therapy (anti-CD70 conjugated antibodies, CAR-T cells) or modulation of the tumor microenvironment may represent potential therapeutic mechanisms in treating CD70-expressing gliomas.
Enrichment of CD70 expression in gliomas with epithelioid or sarcomatous features warrants further investigation in a larger cohort of IDH-wild-type glioblastomas. Furthermore, known molecular alterations in these variants (PTEN and TERT promoter mutations in gliosarcoma, and BRAF V600E mutations in E-GBM) could reveal co-existing immunotherapeutic targets. Lastly, while not all tumors with prior radiotherapy expressed CD70 in our cohort, the marked posttherapeutic expression observed here suggests this could represent a feasible treatment target as part of a multimodal approach.
